stockrow
Friday 6 November 2026
Export SGHT’s income statement to Excel — free account
Sight Sciences, Inc.
SGHT Healthcare Medical Devices
Sight Sciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $77.4 million, down 3.13% from fiscal 2024.
- Revenue
- +25.2%
- EPS
- +25.0%
- Free cash flow
- +72.2%
- Total debt
- +2.40%
Quarter to September 2026, against a year earlier
10.04
0.28
+2.87%
Follow SGHT
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 From the 10-Q filed 4 Nov | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
5.35 | 2.56 | 3.54 | 5.84 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(226.35) | (28.93) | (52.17) | (214.81) | |
P/B ratio |
6.47 | 3.77 | 5.59 | 10.50 | |
Price to Tangible BV |
6.47 | 3.77 | 5.59 | 10.50 | |
EV/Sales |
4.71 | 2.00 | 3.08 | 5.43 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(12.26) | (6.33) | (11.04) | (28.34) | |
EV/FCF |
(12.11) | (6.26) | (10.99) | (28.36) | |
Quick Ratio |
9.22 | 5.26 | 4.45 | 4.51 | |
Current Ratio |
10.22 | 5.86 | 4.95 | 5.04 | |
Net Debt/EBITDA |
15.52 | 3.68 | 10.98 | 6.31 | |
Debt/Assets |
34.95% | 36.95% | 38.88% | 39.09% | |
Debt/Equity |
0.63 | 0.75 | 0.77 | 0.84 | |
Asset Turnover |
0.60 | 0.66 | 0.74 | 0.80 | |
Operating CF/Net income |
0.44 | 0.54 | 1.27 | 0.35 | |
Capex/Depreciation |
0.46 | (0.18) | (0.06) | (0.19) | |
Interest Coverage |
(2.85) | (9.79) | (3.01) | (4.67) | |
Research and Development Expense of Revenue |
11.95% | 12.93% | 10.74% | 10.86% | |
Selling, General and Administrative Expense of Revenue |
93.30% | 136.28% | 97.27% | 99.67% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
12.50% | 14.48% | 12.67% | 11.78% | |
Graham Net Nets |
0.15 | 0.25 | 0.17 | 0.09 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(9.46%) | (18.83%) | (10.33%) | (5.56%) | |
Free Cash Flow Yield |
(7.27%) | (12.49%) | (7.90%) | (3.28%) | |
Revenue per Share |
0.39 | 0.37 | 0.43 | 0.45 | |
Operating CF per Share |
(0.03) | (0.13) | (0.10) | (0.04) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.03) | (0.13) | (0.10) | (0.04) | |
Cash per Share |
1.76 | 1.58 | 1.46 | 1.40 | |
Shareholders Equity per Share |
1.23 | 1.00 | 0.97 | 0.89 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.23 | 1.00 | 0.97 | 0.89 | |
Free Cash Flow |
(1.67) | (7.09) | (5.68) | (2.47) | |
Working Capital |
101.71 | 88.35 | 80.94 | 81.33 | |
Capital Expenditures |
0.16 | (0.06) | (0.02) | (0.07) | |
Net Current Asset Value |
61.38 | 50.71 | 49.46 | 45.66 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
(0.01) | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
10.27 | 10.01 | 10.50 | 11.56 | |
Average Payables |
1.52 | 2.13 | 1.99 | 2.26 | |
Average Inventory |
7.05 | 6.41 | 5.95 | 7.24 | |
Average Assets |
129.07 | 119.69 | 113.42 | 110.60 | |
Average Common Equity |
75.73 | 65.77 | 61.45 | 56.71 |
Columns are period end dates · fundamentals updated 4 Nov 2026